About: Early outcomes of tocilizumab in adults hospitalized with severe COVID19. An initial report from the Vall dHebron COVID19 prospective cohort study.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Early outcomes of tocilizumab in adults hospitalized with severe COVID19. An initial report from the Vall dHebron COVID19 prospective cohort study. Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Early outcomes of tocilizumab in adults hospitalized with severe COVID19. An initial report from the Vall dHebron COVID19 prospective cohort study.
Creator	Antón, Andrés Salvador, Fernando Almirante, Benito Antón, Simeón Augustin, Salvador Bosch-Nicolau, Pau Durà, Xavier Eremiev-Eremiev, Abiu Espinosa-Pereiro, Juan Espinosa-Pereiro, Nuria Fernández-Hidalgo, Nuria Guillén-Del-Castillo, Alfredo Miarons, Andrés Miarons, Marta Monforte-Pallarés, Arnau Montalvá, Júlia Pérez-Hoyos, Santiago Sampol, Júlia Sellarés-Nadal, Juan Sellarés-Nadal, Júlia Sempere-González, Abiu Sempere-González, Arnau
source	MedRxiv
abstract	Background: Modulation of the immune system to prevent lung injury is being widely used against the new coronavirus disease (COVID19) despite the scarcity of evidence. Methods: We report preliminary results from the Vall dHebron prospective cohort study at Vall dHebron University Hospital, in Barcelona (Spain), including all consecutive patients who had a confirmed infection with the severe acute respiratory syndrome coronavirus2 (SARSCoV2) and who were treated with tocilizumab until March 25th. The primary endpoint was mortality at 7 days after tocilizumab administration. Secondary endpoints were admission to the intensive care unit, development of ARDS and respiratory insufficiency among others. Results: 82 patients with COVID19 received at least one dose of tocilizumab. The mean (SD) age was 59.1 (19.8) years, 63% were male, 22% were of non Spanish ancestry, and the median (IQR) ageadjusted Charlson index at baseline was 3 (1 to 4) points. Respiratory failure and ARDS developed in 62 (75.6%) and 45 (54.9%) patients, respectively. Median time from symptom onset to ARDS development was 8 (5 to 11) days. The median time from symptom onset to the first dose of tocilizumab was 9 (7 to 11) days. Mortality at 7 days was 26.8%. Hazard ratio for mortality was 3.3; 95% CI, 1.3 to 8.5 (age adjusted hazard ratio for mortality 2.1; 95% CI, 0.8 to 5.8) if tocilizumab was administered after the onset of ARDS. Conclusion: Time from lung injury onset to tocilizumab administration may be critical to patient recovery. Our preliminary data could inform bedside decisions until more data from clinical trials becomes available.
has issue date	2020-05-12(xsd:dateTime)
bibo:doi	10.1101/2020.05.07.20094599
has license	medrxiv
sha1sum (hex)	1b6e9ee648a6ffc0297d06e73d3dea87897764f9
schema:url	https://doi.org/10.1101/2020.05.07.20094599
resource representing a document's title	Early outcomes of tocilizumab in adults hospitalized with severe COVID19. An initial report from the Vall dHebron COVID19 prospective cohort study.
resource representing a document's body	covid:1b6e9ee648a6ffc0297d06e73d3dea87897764f9#body_text
is schema:about of	named entity 'Spain' named entity 'Barcelona' named entity 'number' named entity 'physician' named entity 'physician' named entity 'physician' named entity 'tocilizumab' named entity 'data curation' named entity 'database design' named entity 'Spain' named entity 'tocilizumab' named entity 'Consulting physician' named entity 'COVID-19' named entity 'preprint' named entity 'tocilizumab' named entity 'preprint' named entity 'lung' named entity 'lung' named entity 'Charlson index' named entity 'preprint' named entity 'IL-6' named entity 'haemophagocytic lymphohistiocytosis' named entity 'preprint' named entity 'PaO2/FiO2 ratio' named entity 'peer review' named entity 'radiographs' named entity 'asthma' named entity 'medRxiv' named entity 'Urea' named entity 'preprint' named entity 'respiratory failure' named entity 'liver enzymes' named entity 'symptom' named entity 'septic shock' named entity 'medRxiv' named entity 'symptom' named entity 'preprint' named entity 'medRxiv' named entity 'respiratory insufficiency' named entity 'WHO' named entity 'medical history' named entity 'medRxiv' named entity 'ventilation support' named entity 'COVID-19' named entity 'glomerular filtration rate' named entity 'China' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'obesity' named entity 'hypertension' named entity 'immune response' named entity 'arterial oxygen saturation' named entity 'cytokine' named entity 'cytokine' named entity 'fraction of inspired oxygen' named entity '95% CI' named entity 'Charlson index' named entity 'China' named entity 'respiratory failure' named entity 'FiO2' named entity 'pneumonia severity index' named entity 'oxygen saturation' named entity 'preprint' named entity 'inflammation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software